Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. - Wikidata - awgldk - TriplyDB

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

http://www.wikidata.org/entity/Q35900767

about

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis What is the Best Treatment for a Cancer Patient with Thrombosis?Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Integration of genetic, clinical, and INR data to refine warfarin dosing.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.A review of a priori regression models for warfarin maintenance dose prediction.Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Factors affecting time to maintenance dose in patients initiating warfarin.Genome-wide association study of warfarin maintenance dose in a Brazilian sample A multi-factorial analysis of response to warfarin in a UK prospective cohort Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response.Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.The Clinical Pharmacokinetics and Pharmacodynamics of Warfarin When Combined with Compound Danshen: A Case Study for Combined Treatment of Coronary Heart Diseases with Atrial Fibrillation.A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

P2860

Q27002899-4F4B7F28-CB94-468F-A386-F45A5A1EE0E9 Q27009514-E0A963DD-5BC4-4B45-86A9-80C1D52AB88D Q27334876-F033A36A-3B3C-4646-9266-5E769388E964 Q28276514-49E29FA6-7959-487E-A92B-F97668BEF3CC Q33550741-65A71B13-EC03-4F90-8780-416C903437BC Q33770184-F8CC191C-950C-4805-AB3A-89E383D69516 Q34402967-693531EB-6276-4E0F-98AF-06D6BD99E1F4 Q34690708-17B6C0CE-4C87-45E8-9532-54FE0BDEAB70 Q35485247-D151F258-D32D-483D-997C-78A62F2995E7 Q35640455-E99CDA89-9A57-4006-9BA2-8138CE24EEC4 Q36060109-9565A3D4-C6A4-4B25-8A39-2EECD8749380 Q36068687-BD1A78E5-0B93-4800-BB0B-47A9EA47D293 Q36433323-5C1FC4D5-BE00-4278-92E8-B74B8EF563B4 Q36487475-5B9B2FA2-AC32-4D07-BFB2-5C40241719AE Q37019459-65BB27C8-8830-418B-97C8-D6B1C556B365 Q37770117-CE36448D-F7EB-48A4-8367-023BE393D591 Q37863679-69615D25-D5D3-41C1-A60E-4041661713B4 Q38042441-6BCEF55D-0836-49E1-8273-F2BC9EC7813B Q38078754-D9CD6010-61E2-4540-92B3-F3EBECF72DB2 Q38388873-AC9D8274-75AB-4DDC-9A87-70EDE88B2B43 Q38723170-2E0C2A2A-69C7-4658-B02E-248B6E829C74 Q39483670-A63E7F01-5908-42B0-83BD-49A52631D95C Q41478624-63DC221E-625F-40E3-8136-CED364AFA8C9 Q47137383-A00ADDD7-3B6A-42C6-97FC-97D79E1B4FAF Q51514655-3D119678-5509-4509-A76B-40C095AC8F92 Q53094061-A4C40A4B-FD3F-4570-B8F9-655EAED0E503

P2860

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

http://www.wikidata.org/entity/Q35900767

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Genetic and environmental fact ...... therapy: a prospective study.

@ast

Genetic and environmental fact ...... therapy: a prospective study.

@en

type

label

Genetic and environmental fact ...... therapy: a prospective study.

@ast

Genetic and environmental fact ...... therapy: a prospective study.

@en

prefLabel

Genetic and environmental fact ...... therapy: a prospective study.

@ast

Genetic and environmental fact ...... therapy: a prospective study.

@en

P1433

Q35900767-CEADC244-71C5-4D86-B53F-6E58FF0A01D4

P1476

Q35900767-4EBDFE68-8F92-48A1-B0A4-3D3804C53877

P2093

Q35900767-02D4FDF3-ABAF-4850-8B4C-C2C37DB06C72

Q35900767-205FF32F-982E-411F-9D9B-F7E3826CB86E

Q35900767-2F389FD3-304C-46BB-A864-C6C44376BD98

Q35900767-65183723-602B-435D-BDC0-B1C273169EDC

Q35900767-6CCAC6FD-CD9F-4A20-86E3-DCD04699BB50

Q35900767-733E10E8-E2B2-427F-8A73-FB4BA7CD90C8

Q35900767-8EF7E7C6-77F6-42A7-881F-10D46F7EAD7F

Q35900767-B29EF57D-8915-488F-9A37-B0A5AA1D4B16

Q35900767-B70FF3EB-D0C2-44C1-9576-B1FE29C4087E

Q35900767-DEED8462-AAC7-4A4F-8EF5-AC5A4078C2AD

P2860

Q35900767-0297842F-EC5D-41F5-AA24-2FAF7708B0D1

Q35900767-0E5C2B67-A328-44D1-AB97-766765B76070

Q35900767-166762D1-264A-4E27-880A-2105D96F3EBF

Q35900767-26BADD68-DA2C-4145-83E6-2803BD75B961

Q35900767-27460848-8A4B-4126-B6C8-9625621E8F1E

Q35900767-38BEACB8-55EE-4ED7-9AFC-52F0DF913681

Q35900767-38E5404F-D806-42DA-B4D8-88F34310F3F7

Q35900767-3C079504-5717-4F7C-B32D-29A373E35BFA

Q35900767-3CFF2367-780F-484C-B1BA-CD3A49E3E20C

Q35900767-3DEFEEBC-79F8-4EBC-B544-0E4019DFC822

P304

Q35900767-2874FF5B-0DFC-4BC9-920C-95D2787424FB

P31

Q35900767-8BE67978-CE81-4FB8-A10F-95CBC7199E54

P356

Q35900767-4B4B23A6-0A96-4A22-8A82-63378423EB15

P433

Q35900767-7E4F47AE-5946-45CA-B40A-1E8F83279189

P478

Q35900767-41DFE2FA-511F-4700-95AB-07175908EEE4

P50

Q35900767-020FC7E7-4AE9-4F44-8CC0-09ADE1412C7C

Q35900767-68B1C80F-385D-468F-8974-BC4613355426

Q35900767-C072A801-A5EC-442F-9D21-69A752DC3D32

Q35900767-CB58826A-6392-4544-9EC4-F1E8A3425537

Q35900767-CD9D83A8-E6F0-4E76-B85C-C5C905B4AEF4

P577

Q35900767-F279824B-F828-489D-B65A-1837741C45E3

P698

Q35900767-80DAF4AD-1F85-4DF5-A7A9-3EEF41DBB6B3

P932

Q35900767-D2A31C0E-3B58-4344-B73C-10CD7B21AB41

P356

FPC.0B013E3283317AB5

P1433

Pharmacogenetics and Genomics

P1476

Genetic and environmental fact ...... therapy: a prospective study.

@en

P2093

Alison Coffey

http://www.w3.org/2001/XMLSchema#string

Andrea L Jorgensen

http://www.w3.org/2001/XMLSchema#string

Andrew Keniry

http://www.w3.org/2001/XMLSchema#string

Anita Hanson

http://www.w3.org/2001/XMLSchema#string

Brian Kevin Park

http://www.w3.org/2001/XMLSchema#string

Cheng H Toh

http://www.w3.org/2001/XMLSchema#string

David Fitzmaurice

http://www.w3.org/2001/XMLSchema#string

Diane van Eker

http://www.w3.org/2001/XMLSchema#string

Farhad Kamali

http://www.w3.org/2001/XMLSchema#string

Jieying Eunice Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks

Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Costing in economic evaluation

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

P304

800-812

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E3283317AB5

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

Paula Williamson

Dyfrig A. Hughes

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19752777

http://www.w3.org/2001/XMLSchema#string

P932

3330749

http://www.w3.org/2001/XMLSchema#string